Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists
作者:Xing-Wu Jiang、Bei-Er Jiang、Hao Liu、Zhi-Tao Liu、Long-Long Hu、Mingyao Liu、Weiqiang Lu、Han-Kun Zhang
DOI:10.1016/j.ejmech.2018.08.075
日期:2018.10
known as free fatty acid receptor 1 (FFAR1), is a member of G protein-coupled receptors (GPCR) family and has emerged as an attractive target for the treatment of type 2 diabetes mellitus. So far, most of the synthetic GPR40 agonists, including several drug candidates discontinued in clinical trials, were derived from the phenylpropionic acid scaffold. For discovering novel GPR40 agonists with diverse
GPR40,也称为游离脂肪酸受体1(FFAR1),是G蛋白偶联受体(GPCR)家族的成员,已成为治疗2型糖尿病的引人注目的靶标。到目前为止,大多数合成的GPR40激动剂,包括在临床试验中已停止使用的几种候选药物,均来自苯丙酸支架。为了发现具有不同化学结构的新型GPR40激动剂,在一系列生物测定中设计,合成和评估了一系列苯丙酸衍生物。与TAK-875相比,该系列中最有效的化合物9显示出亚微摩尔激动剂活性和类似的激动功效。另外,化合物9能够剂量依赖性地扩增胰腺β细胞系MIN6中的葡萄糖刺激的胰岛素分泌(GSIS),这可以被选择性的GPR40拮抗剂GW1100逆转。此外,在正常C57BL / 6小鼠的口服葡萄糖耐量试验中,发现化合物9具有有效的降糖作用。